459 related articles for article (PubMed ID: 22098029)
1. Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies.
Masui K; Cloughesy TF; Mischel PS
Neuropathol Appl Neurobiol; 2012 Jun; 38(3):271-91. PubMed ID: 22098029
[TBL] [Abstract][Full Text] [Related]
2. Molecularly based management of gliomas in clinical practice.
Rudà R; Pellerino A; Magistrello M; Franchino F; Pinessi L; Soffietti R
Neurol Sci; 2015 Sep; 36(9):1551-7. PubMed ID: 26194534
[TBL] [Abstract][Full Text] [Related]
3. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
Dahlrot RH
Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
[TBL] [Abstract][Full Text] [Related]
5. [Molecular Genetics as Best Evidence in Glioma Diagnostics].
Masui K; Komori T
Brain Nerve; 2016 Mar; 68(3):253-61. PubMed ID: 27001774
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylated mTOR and YAP serve as prognostic markers and therapeutic targets in gliomas.
Liu M; Lin Y; Zhang XC; Tan YH; Yao YL; Tan J; Zhang X; Cui YH; Liu X; Wang Y; Bian XW
Lab Invest; 2017 Nov; 97(11):1354-1363. PubMed ID: 28759011
[TBL] [Abstract][Full Text] [Related]
7. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.
Weller M; Weber RG; Willscher E; Riehmer V; Hentschel B; Kreuz M; Felsberg J; Beyer U; Löffler-Wirth H; Kaulich K; Steinbach JP; Hartmann C; Gramatzki D; Schramm J; Westphal M; Schackert G; Simon M; Martens T; Boström J; Hagel C; Sabel M; Krex D; Tonn JC; Wick W; Noell S; Schlegel U; Radlwimmer B; Pietsch T; Loeffler M; von Deimling A; Binder H; Reifenberger G
Acta Neuropathol; 2015 May; 129(5):679-93. PubMed ID: 25783747
[TBL] [Abstract][Full Text] [Related]
8. The Role of Molecular Diagnostics in the Management of Patients with Gliomas.
Wirsching HG; Weller M
Curr Treat Options Oncol; 2016 Oct; 17(10):51. PubMed ID: 27501915
[TBL] [Abstract][Full Text] [Related]
9. Molecular diagnostics of gliomas: the clinical perspective.
Tabatabai G; Stupp R; van den Bent MJ; Hegi ME; Tonn JC; Wick W; Weller M
Acta Neuropathol; 2010 Nov; 120(5):585-92. PubMed ID: 20862485
[TBL] [Abstract][Full Text] [Related]
10. Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System.
Komori T
Lab Invest; 2022 Feb; 102(2):126-133. PubMed ID: 34504304
[TBL] [Abstract][Full Text] [Related]
11. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
12. Molecular and genetic pathways in gliomas: the future of personalized therapeutics.
Grant R; Kolb L; Moliterno J
CNS Oncol; 2014 Mar; 3(2):123-36. PubMed ID: 25055018
[TBL] [Abstract][Full Text] [Related]
13. Molecular profiling of gliomas: potential therapeutic implications.
Alentorn A; Duran-Peña A; Pingle SC; Piccioni DE; Idbaih A; Kesari S
Expert Rev Anticancer Ther; 2015; 15(8):955-62. PubMed ID: 26118895
[TBL] [Abstract][Full Text] [Related]
14. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.
Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K
Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806
[TBL] [Abstract][Full Text] [Related]
15. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
[TBL] [Abstract][Full Text] [Related]
16. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
17. Molecular markers in glioma.
Ludwig K; Kornblum HI
J Neurooncol; 2017 Sep; 134(3):505-512. PubMed ID: 28233083
[TBL] [Abstract][Full Text] [Related]
18. NDRG1 prognosticates the natural course of disease in WHO grade II glioma.
Blaes J; Weiler M; Sahm F; Hentschel B; Osswald M; Czabanka M; Thomé CM; Schliesser MG; Pusch S; Luger S; Winkler F; Radbruch A; Jugold M; Simon M; Steinbach JP; Schackert G; Tatagiba M; Westphal M; Tonn JC; Gramatzki D; Pietsch T; Hartmann C; Glimm H; Vajkoczy P; von Deimling A; Platten M; Weller M; Wick W
J Neurooncol; 2014 Mar; 117(1):25-32. PubMed ID: 24395351
[TBL] [Abstract][Full Text] [Related]
19. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic and predictive factors for gliomas in adults].
Frenel JS; Botti M; Loussouarn D; Campone M
Bull Cancer; 2009 Apr; 96(4):357-67. PubMed ID: 19357011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
